Diazepinomicin - Amo Pharma
Alternative Names: AMO 01; BU-4664L; ECO 04601; ECO 4601; TLN 4601Latest Information Update: 03 Jul 2023
At a glance
- Originator Ecopia BioSciences
- Developer AMO Pharma; BELLUS Health
- Class Alkaloids; Antineoplastics; Benzodiazepinones; Small molecules
- Mechanism of Action Apoptosis stimulants; Ras protein inhibitors; TSPO protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Telomeric 22q13 Monosomy Syndrome
- No development reported Fragile X syndrome
- Discontinued Glioblastoma
Most Recent Events
- 28 Jun 2023 BELLUS Health has been acquired by GSK
- 29 Nov 2022 Diazepinomicinis still in phase-II trials for Telomerase-22q13 monosomy syndrome in USA (Amo Pharma pipeline; November 2022)
- 28 Jul 2019 No recent reports of development identified for phase-I development in Fragile-X-syndrome in USA (IV, Infusion)